Randomized phase II clinical trials are also exploring combinations of DC vaccines with radiation therapy and pre-vaccination IFN-α (NCT01973322), modified tumor cell-based vaccines with ipilimumab (NCT02054520), and DC vaccines with targeted tyrosine kinase inhibitors (NCT01876212). Here, IFNA1 is linked to neoplasm.